Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SkyePharma Inc. has changed its name to Pacira Pharmaceuticals Inc. in order to reflect its transformation from a former business unit of SkyePharma plc to an independent, private company. Pacira Pharmaceuticals has also developed a new corporate logo and website.
Subscribe to our email newsletter
SkyePharma Inc was divested by its former parent company SkyePharma plc in March 2007 and was subsequently acquired by San Diego-based Pacira Inc (formerly Blue Acquisition Corporation), which is now controlled and funded by a group of life science investment firms.
The new investor group made the investment in Pacira Pharmaceuticals based on the significant development opportunity of its technology and of DepoBupivacaine, a sustained-release local analgesic now in clinical development for use in the $5.7 billion postoperative pain market.
Fred Middleton, chairman of Pacira Inc, stated: “Pacira Pharmaceuticals now has the resources necessary to pursue the commercial potential for DepoBupivacaine, as well as to deliver on the promise of our proprietary sustained-release technologies.”
“Our new name, Pacira Pharmaceuticals, reflects strong local commitment of more than a decade as a San Diego-based product R&D organization. In the future we plan to consider directly marketing our own products still in development, as well as in-licensing products in core therapeutic areas of interest, such as pain,” Mr Middleton continued.